Navigating competition risk in Türkiye’s healthcare sector is the focus of this evening roundtable. Date, venue, sponsor and supporting partner are to be confirmed.
The Competition Law Roundtable is a focused, senior-level discussion bringing together in-house legal counsel who advise their organisations on competition and antitrust matters, with a particular emphasis on the rapidly evolving healthcare, pharmaceutical and life sciences sectors in Türkiye.
Designed as an intimate and highly interactive forum, the roundtable will provide participants with an opportunity to discuss some of the most significant competition-law developments currently affecting businesses operating in the Turkish healthcare market.
Rather than following a conventional conference format, the event will be built around peer-to-peer discussion, practical experience and open exchange between in-house lawyers. The objective is to create a setting in which participants can explore how recent Competition Authority activity may translate into real-world risk for their businesses, while sharing approaches to compliance, investigations, commercial decision-making and engagement with internal stakeholders.
Why now?
Competition law scrutiny of the healthcare and pharmaceutical sectors in Türkiye is entering an especially significant period.
On 10 August 2026, the Turkish Competition Authority announced the preliminary findings of its extensive pharmaceutical sector review. The study examines the pharmaceutical value chain from research and development through manufacturing, licensing, reimbursement, distribution and ultimately access by patients. As part of the review, the Authority examined approximately 350 patent disputes and more than 50,000 public procurement items covering 175 active pharmaceutical ingredients.
Perhaps most importantly for businesses, the preliminary report considers measures aimed at preventing patent, licensing and reimbursement procedures from being used in ways that may delay competitor entry. It also proposes potential changes to distribution and procurement structures, including a move away from sole-authorised-seller arrangements within the Health Market system towards models intended to increase intra-brand competition.
These developments make competition law an increasingly strategic issue for legal teams operating in healthcare. Questions that may once have been considered primarily regulatory, commercial or market-access matters can now carry an important competition-law dimension.
Key themes for discussion
The roundtable will explore the practical implications of this changing enforcement environment, including the Turkish Competition Authority’s new pharmaceutical sector review.
Participants will consider what the Authority’s latest sector review may tell us about the direction of competition policy in pharmaceuticals and healthcare. Attention will be given to the Authority’s examination of market entry, patent strategies, licensing, reimbursement, public procurement and distribution structures, and what the proposed recommendations could mean for companies operating throughout the pharmaceutical supply chain.
The discussion will consider not simply what the Authority has said, but what in-house counsel should be thinking about now: where internal practices may need to be reviewed, which commercial arrangements could attract greater scrutiny, and how legal teams should prepare for a potentially more interventionist environment.